Skip to main content
. Author manuscript; available in PMC: 2019 Jan 19.
Published in final edited form as: ACS Chem Biol. 2017 Dec 5;13(1):91–99. doi: 10.1021/acschembio.7b00827

Figure 2.

Figure 2

Apratyramide (1) is an inducer of VEGF-A and other growth factors. A) Transcript level of VEGF-A in HCT116 (human colon cancer) cells, 16 h. B) Transcript level of VEGF-A in CCD-18Co (human normal colon) cells, 16 h. C) Antiproliferative effect of 1 on HCT116 and CCD-18Co cells, 48 h. D) Transcript level of VEGF-A in HaCaT cells after 4 h and 12 h treatment with 30 μM of 1. E) Transcript level of VEGF-A in HaCaT cells after 16 h. F) Level of VEGF-A secretion from HaCaT after 24 h. G) Antiproliferative activity of 1 on HaCaT cells, 24 h. H) Transcript level of PDGFB in HaCaT cells, 16 h. I) Transcript level of bFGF in HaCaT cells, 16 h. Data are presented as mean + SD, *P < 0.05, **P < 0.01, ***P < 0.001, compared to control using unpaired t test (n = 3).